TAFINLAR
Total Payments
$333.8M
Transactions
2,320
Doctors
865
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $19.5M | 211 | 152 |
| 2023 | $24.0M | 101 | 5 |
| 2022 | $30.3M | 73 | 3 |
| 2021 | $41.7M | 117 | 15 |
| 2020 | $26.8M | 122 | 21 |
| 2019 | $49.8M | 219 | 56 |
| 2018 | $83.9M | 776 | 432 |
| 2017 | $57.9M | 701 | 341 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $333.7M | 1,053 | 99.9% |
| Consulting Fee | $110,945 | 26 | 0.0% |
| Travel and Lodging | $33,524 | 73 | 0.0% |
| Food and Beverage | $23,834 | 1,162 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,796 | 2 | 0.0% |
| Education | $34.52 | 4 | 0.0% |
Payments by Type
Research
$333.7M
1,053 transactions
General
$176,133
1,267 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED PHASE II TRIAL OF INTERMITTENT VERSUS CONTINUOUS DOSING OF DABRAFENIB AND TRAMETINIB IN BRAFV600E K MUTANT MELANOMA | Novartis Pharmaceuticals Corporation | $171.4M | 0 |
| ROAR A PHASE II OPEN LABEL STUDY IN SUBJECTS WITH BRAF V600E MUTATED RARE CANCERS WITH SEVERAL HISTOLOGIES TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF THE COMBINATION THERAPY OF DABRAFENIB AND TRAMETINIB | Novartis Pharmaceuticals Corporation | $34.8M | 1 |
| A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E K Mutant Melanoma | Novartis Pharmaceuticals Corporation | $23.1M | 0 |
| PHASE II OPEN LABEL GLOBAL STUDY TO EVALUATE THE EFFECT OF DABRAFENIB TREATMENT IN CHILDREN AND ADOLESCENT SUBJECTS WITH BRAF V600 MUTATION POSITIVE RELAPSED REFRACTORY OR PROGRESSIVE HGG TUMOR | Novartis Pharmaceuticals Corporation | $17.2M | 1 |
| THE BAMM TRIAL BRAF AUTOPHAGY AND MEK INHIBITION IN METASTATIC MELANOMA A PHASE I AND OR 2 TRIAL OF DABRAFENIB TRAMETINIB AND HYDROXYCHLOROQUINE IN PATIENTS WITH ADVANCED BRAF MUTANT MELANOMA | Novartis Pharmaceuticals Corporation | $9.5M | 0 |
| An open label multi center Phase IV rollover protocol for patients who have completed a prior global Novartis sponsored Tafinlar dabrafenib and or Mekinist trametinib study and are judged by the investigator to benefit from continued treatment | Novartis Pharmaceuticals Corporation | $9.2M | 0 |
| NEOADJUVANT DABRAFENIB AND TRAMETINIB COMPARED TO UPFRONT SURGERY IN PATIENTS WITH CLINICAL STAGE IIIB AND OR C OR OLIGOMETASTATIC STAGE IV MELANOMA COMBI NEO | Novartis Pharmaceuticals Corporation | $9.1M | 0 |
| AN OPEN LABEL MULTI CENTER PHASE IV ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLOBAL NOVARTIS SPONSORED TAFINLAR DABRAFENIB AND OR MEKINIST TRAMETINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT | Novartis Pharmaceuticals Corporation | $8.8M | 0 |
| A RANDOMIZED PHASE 2 STUDY OF SINGLE AGENT GSK2118436 BRAFI VS COMBINATION REGIMEN GSK2118436 BRAFI AND GSK1120212 MEKI IN PATIENTS WITH BRAF MUTATED THYROID CARCINOMA | Novartis Pharmaceuticals Corporation | $7.9M | 0 |
| AN OPEN LABEL, MULTI-CENTER ROLL-OVER STUDY TO ASSESS LONG-TERM EFFECT IN PEDIATRIC PATIENTS TREATED WITH TAFINLAR (DABRAFENIB) AND/OR MEKINIST (TRAMETINIB) | Novartis Pharmaceuticals Corporation | $6.7M | 0 |
| PHASE 1/11 TRIAL OF DABRAFENIB/ TRAMETINIB / HYDROCHLOROQUINEFOR BRAF V600E MUTANT OR TRAMETINIB / HYDROXYCHLOROQUINEFOR BRAF FUSION / DUPLICATION POSITIVE OR NF-1 ASSOCIATED RECURRENT /REFRACTORY GLIOMAS IN CHILDREN AND YOUNG ADULTS | Novartis Pharmaceuticals Corporation | $5.6M | 0 |
| An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) | Novartis Pharmaceuticals Corporation | $5.0M | 0 |
| AN OPEN LABEL PILOT STUDY OF COMBINATION THERAPY WITH DABRAFENIB GSK2118463 AND TRAMETINIB GSK1120212 IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA PH I | Novartis Pharmaceuticals Corporation | $4.0M | 0 |
| Phase 1/11 trial of Dabrafenib/ Trametinib / Hydrochloroquinefor BRAF V600E Mutant or Trametinib / Hydroxychloroquinefor BRAF Fusion / Duplication positive or NF-1 Associated recurrent /Refractory gliomas in children and young adults | Novartis Pharmaceuticals Corporation | $3.0M | 0 |
| A PHASE II STUDY OF THE BRAF INHIBITOR DABRAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH THE MEK INHIBITOR TRAMETINIB IN SUBJECTS WITH BRAF V600E MUTATION POSITIVE METASTATIC STAGE IV NONSMALL CELL LUNG CANCER | Novartis Pharmaceuticals Corporation | $2.8M | 2 |
| PHASE I AND OR IIA 2PART MULTI CENTER SINGLE ARM OPEN LABEL STUDY TO DETERMINE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ORAL DABRAFENIB IN PEDIATRIC SUBJECTS AGED 1 MONTH TO LESS THAN 18 YEARS WITH ADVANCED BRAF V600 MUTATION POSITIVE SOLID TUMORS | Novartis Pharmaceuticals Corporation | $2.3M | 1 |
| AN OPEN LABEL DOSE ESCALATION PHASE I AND OR II STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS PHARMACODYNAMICS AND CLINICAL ACTIVITY OF THE BRAF INHIBITOR GSK2118436 IN COMBINATION WITH THE MEK INHIBITOR GSK1120212 IN SUBJECTS WITH BRAF MUTANT METASTAT | Novartis Pharmaceuticals Corporation | $1.6M | 0 |
| A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in previously treated patients with locally advanced or metastatic, radio-active iodine refractory BRAFV600E mutation-positive Differentiated Thyroid Cancer | Novartis Pharmaceuticals Corporation | $1.6M | 0 |
| ROAR A PHASE II OPEN LABEL STUDY IN SUBJECTS WITH BRAF V600E MUTATED RARE CANCERS WITH SEVERAL HISTOLOGIES TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF THE COMBINATION THERAPY OF DABRAFENIB AND TRAMETINIB | NOVARTIS PHARMACEUTICALS CORPORATION | $1.1M | 1 |
| COMBIV A PHASE III RANDOMISED OPEN LABEL STUDY COMPARING THE COMBINATION OF THE BRAF INHIBITOR DABRAFENIB AND THE MEK INHIBITOR TRAMETINIB TO THE BRAF INHIBITOR VEMURAFENIB IN SUBJECTS WITH UNRESECTABLE STAGE IIIC OR METASTATIC STAGE IV BRAF V600EK MUTATI | Novartis Pharmaceuticals Corporation | $925,102 | 0 |
Top Doctors Receiving Payments for TAFINLAR — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Medical Oncology | Aurora, CO | $6,469 | 5 |
| , M.D | Hematology & Oncology | Burr Ridge, IL | $6,226 | 4 |
| , MD | Hematology & Oncology | Jacksonville, FL | $5,448 | 4 |
| , MD | Plastic Surgery | Hershey, PA | $5,045 | 8 |
| , MD | Surgery | Portland, OR | $5,040 | 6 |
| , MD | Medical Oncology | Boston, MA | $4,885 | 6 |
| Michael Postow | Internal Medicine | Boston, MA | $4,761 | 7 |
| , MD | Internal Medicine | Washington, DC | $4,087 | 4 |
| , M.D | Hematology | Rochester, MN | $4,057 | 2 |
| , M.D | Student in an Organized Health Care Education/Training Program | Pittsburgh, PA | $4,045 | 1 |
| , MD | Surgery | Morristown, NJ | $3,979 | 4 |
| , MD | Hematology & Oncology | Los Angeles, CA | $3,788 | 6 |
| , MD PHD | Pediatric Hematology-Oncology | Boston, MA | $3,750 | 1 |
| , MD | Surgery | Houston, TX | $3,547 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Houston, TX | $3,440 | 2 |
| , MD | Internal Medicine | San Francisco, CA | $3,350 | 1 |
| Steven Herbert | — | Rochester, NY | $3,180 | 3 |
| , D.O | Medical Oncology | Los Angeles, CA | $2,987 | 7 |
| , M.D | Dermatology | New York, NY | $2,666 | 6 |
| , MD | Medical Oncology | Manchester, MA | $2,620 | 3 |
| , M.D | Pediatric Hematology-Oncology | Phoenix, AZ | $2,584 | 3 |
| , M.D | Hematology & Oncology | Fort Smith, AR | $2,540 | 3 |
| , MD | Medical Oncology | Grand Rapids, MI | $2,489 | 3 |
| , M.D | Hematology & Oncology | Leawood, KS | $1,965 | 1 |
| , MD | Internal Medicine | Detroit, MI | $1,735 | 2 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $331.8M
- NOVARTIS PHARMACEUTICALS CORPORATION $2.1M
- Novartis Pharma AG $7,594
Product Information
- Type Drug
- Total Payments $333.8M
- Total Doctors 865
- Transactions 2,320
About TAFINLAR
TAFINLAR is a drug associated with $333.8M in payments to 865 healthcare providers, recorded across 2,320 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $19.5M was paid across 211 transactions to 152 doctors.
The most common payment nature for TAFINLAR is "Unspecified" ($333.7M, 99.9% of total).
TAFINLAR is associated with 20 research studies, including "A RANDOMIZED PHASE II TRIAL OF INTERMITTENT VERSUS CONTINUOUS DOSING OF DABRAFENIB AND TRAMETINIB IN BRAFV600E K MUTANT MELANOMA" ($171.4M).